Autoresearch: Has 2H 2026 hospital data shown deferred elective / outpatient volume snapping back at HCA, Tenet, UHS, or CYH? Current uncompensated-care evidence? Did Congress extend the ACA enhanced premium tax credits?

Generated by /autoresearch on 2026-09-19. Synthesized across 3 rounds from 14 successfully fetched pages (2 timeouts; 1 thin CBO HTML), anchored by Grokipedia Affordable_Care_Act and premium_tax_credit (encyclopedic primers only — not used as sources for 2026 claims). See Provenance. Treat as raw material — review before promoting into a project or thread. Context: vault/projects/stock-market Research-only. No buy/sell/size.

Summary

As of this 19 Sep 2026 pass, Congress has not enacted a full or partial extension of the ACA enhanced premium tax credits (EPTCs / enhanced APTCs) that expired 31 Dec 2025. H.R. 1834 (a three-year restoration through 2028) passed the House 230–196 on 8 Jan 2026 and, on congress.gov, last moved on 10 Feb 2026 (Senate second reading; Calendar No. 319) — tracker status remains Passed House, not Became Law (congress.gov H.R. 1834; history; text). Hospital issuers still speak of expiration as a live 2026 fact on 24 Jul and 9 Sep 2026 (HCA Q2 call; HCA Wells Fargo conference).

Q3 2026 10-Qs / earnings are not printed. No fetched issuer IR, 10-Q, or transcript contains a 2H 2026 same-facility surgical snapback. The latest printed operating quarter is Q2 2026 (ended 30 Jun). HCA’s 9 Sep 2026 conference line is explicit: guidance “does not consider a rebound in surgery” (Wells Fargo). Tenet’s CFO said Q2 exchange-erosion trends are expected to “roughly continue into Q3 and Q4” (THC Q2 call).

What is in the Q2 primaries: HCA same-facility inpatient surgeries −2.3% and outpatient surgeries −3.4%; exchange equivalent admissions −15% with “almost one for one” migration to uninsured; uninsured admissions +23.4% same-facility; pretax exchange payer-mix hit ~$400 million in Q2; FY exchange assumption raised to −$1.0 to −$1.2 billion; uncompensated-care cost $1.445 billion in Q2 vs $1.116 billion a year earlier (HCA IR 24 Jul 2026; HCA 10-Q; HCA Q2 call). THC/UHS/CYH also attribute mix and/or elective softness to exchange attrition; none of those Q2 prints show deferred volume “snapping back.”

Findings

Enhanced APTCs: expired; House-only extension; not law as of this pass

The ARPA/IRA enhancement of IRC §36B (lower applicable percentages; no 400% FPL cap) sunset for tax years beginning after 31 Dec 2025. The statutory PTC itself did not sunset — only the temporary enhancement (Grokipedia primer, not used for 2026 outcomes; legislative recap ASTHO 20 Jan 2026).

H.R. 1834 §1 would have rewritten “through 2025” / “before January 1, 2026” to “through 2028” / “before January 1, 2029” and applied the change to taxable years beginning after 31 Dec 2025 (congress.gov text). The House passed it 8 Jan 2026, 230–196 (AHA 9 Jan 2026; congress.gov). Congressional Record history lists Senate receipt, a 14 Jan objection to consideration, return of papers, then first/second reading and calendar placement on 9–10 Feb 2026 (history). No fetched congress.gov page records Senate passage, presentment, or Public Law.

S. 3385 (three-year Senate extension) failed the 60-vote cloture bar in Dec 2025; ASTHO (20 Jan) still described CARE Act talks as unfinished and wrote that “Congressional efforts to extend the ACA PTCs have stalled” (ASTHO). That ASTHO note is early-2026. Later contemporaneous issuer speech is the check that no stealth extension arrived: HCA CEO Sam Hazen on 24 Jul 2026, “Unfortunately, the enhanced premium tax credits expired at the end of the year” (HCA Q2 call); same framing on 9 Sep 2026 at Wells Fargo (Wells Fargo). UHS’s 8-K exhibit 99.1 states that 2025 legislation “eliminated certain exchange premium tax credits beyond 2025” (UHS EX-99.1).

Do not treat a House-passed bill, a CARE Act draft, or insurer/hospital rumor as an extension. This pass found no enacted full or partial restoration.

Marketplace after expiry (KFF / CBO context — not hospital volume)

KFF (19 May 2026), using CMS/SBM Open Enrollment files plus Wakely and a Feb–Mar survey: 2026 Open Enrollment sign-ups fell by over a million to 23.1 million; average monthly net premium (all consumers) rose 58% from $113 to $178; the earlier 114% figure was KFF’s stay-in-the-same-plan estimate for subsidized enrollees and did not materialize as an all-enrollee average because of bronze buy-down and cliff-exit; average deductible +37% to $3,786; 9% of 2025 Marketplace enrollees said they became uninsured (KFF 19 May 2026). CBO’s Dec 2024 letter (pub. 59230) had projected 2.2 million losing coverage in 2026 if the expansion was not extended and a 4.3% 2026 benchmark-premium effect (CBO 59230 landing; AHA recap of that letter AHA 6 Dec 2024). The CBO HTML page fetched here is a landing stub; the 2.2 million figure is the pre-expiry projection already in the mechanism page, not a 2026 realized census.

KFF’s later state-level effectuated-enrollment article (ASPE ~3 million decline; February effectuated 19.2 million, −12% vs 21.8 million) timed out on fetch this pass — do not treat those search-snippet numbers as fetched.

HCA Q2 2026 / 10-Q: surgical declines, one-for-one uninsured, no 2H rebound in guidance

HCA’s 24 Jul 2026 release (consistent with the 14 Jul preview): Q2 revenue $20.230 billion (+8.7%); same-facility admissions +2.5%, equivalent admissions +2.7%, ER visits +3.6%; same-facility inpatient surgeries −2.3%; same-facility outpatient surgeries −3.4%. Payer-mix shift from patients who “lost coverage on the health insurance exchanges” estimated at ~$400 million unfavorable to income before taxes in Q2 (includes ~$75 million true-up to the Q1 estimate). FY 2026 exchange assumption raised from ($600)–($900) million (24 Apr) to ($1.000)–($1.200) billion (14 Jul). Guidance revised: revenue $77.0–$79.5 billion; Adjusted EBITDA $15.400–$16.100 billion; diluted EPS $28.70–$30.50. Forward-looking language names “the expiration at the end of 2025 of enhanced premium tax credits (“EPTCs”)” among guidance assumptions (HCA IR).

The 10-Q (period ended 30 Jun 2026) repeats the surgical rates (consolidated outpatient surgeries −4.4%, same-facility −3.4%; inpatient −2.3% both bases) and states: “As expected, during the quarter and six months ended June 30, 2026, our revenues from managed care and insurers were unfavorably impacted by the expiration of the EPTCs at the end of 2025 and administrative reforms, both related to insurance purchased through the Exchanges.” Same-facility uninsured admissions +23.4% in Q2 2026 vs Q2 2025 and +15.5% in Q1 2026 vs Q1 2025, “reflect[ing] impacts from the expiration of the EPTCs.” Texas + Florida: 58% of admissions, 73% of uninsured admissions in the quarter (HCA 10-Q).

Uncompensated care (HCA, 10-Q definition = charity + uninsured discounts + implicit price concessions):

Charity-care charges $5.318 billion in Q2 2026 vs $4.112 billion in Q2 2025; estimated charity cost $511 million vs $395 million (HCA 10-Q). These are gross-charge / cost-ratio constructs, not cash write-offs equal to the $400 million pretax mix number.

Transcript attribution (not a snapback): Hazen: exchange equivalent admissions −15%; “We expected some of these patients to shift to other forms of coverage, but this did not happen. Instead, these patients migrated almost one for one to uninsured.” “We believe most of the attrition this year is attributable to the expiration of the enhanced premium tax credits.” Elective inpatient surgeries −6% YTD vs −2% in 2025; emergent inpatient (about two-thirds of inpatient cases) +2%. “HICS demand… is a big piece of it, not the sole piece”; physicians also cite affordability; Medicare inpatient-only list is a smaller channel shift. On a 2H recovery: “We’ll have to see, A.J., as we move through the balance of the year, whether or not we see a recovery from some of the early indicators that we’ve seen in the first six months.” CFO Mike Marks: original 80–85% uninsured-conversion assumption revised to “closer to one for one”; original assumption that newly uninsured would reduce utilization “did not materialize.” FY exchange range −$1.0 to −$1.2 billion on Adjusted EBITDA. Three divisions (Gulf Coast, North Florida, South Atlantic) = ~50% of the company impact; those divisions’ HICS adjusted-admission decline 25–28% H1 (HCA Q2 call).

9 Sep 2026 (still no Q3 print): Hazen: “most of our elective surgical declines were attributable to the HIX classification… the lion’s share of the decline.” “Our guidance for the balance of the year does not consider a rebound in surgery. It sort of continues throughout the balance of the year.” Deductible-season ease in Q4 is framed as possible, not observed. IR on the same stage: “the guidance assumes that… surgical volumes remain about the same” in 2H (Wells Fargo).

That is issuer guidance that the step-3 falsifier (2H snapback) has not printed, not a Q3 actual.

Tenet (THC): exchange admissions down; surgeries slightly down; outlook raised; mix, not snapback

Tenet’s 23 Jul 2026 8-K exhibit 99.1: Q2 net operating revenues $5,628 million; Adjusted EBITDA $1.304 billion (+16.3%). Same-hospital admissions +2.3%, adjusted admissions +2.6%, ER visits +2.0%; hospital surgeries −0.7%; outpatient visits +0.1% (Q2 2025 comparison column shows outpatient visits −3.2% in the year-ago quarter). USPI same-facility system-wide surgical cases −1.2% with revenue/case +6.3%. Hospital net revenues +6.0% “partially offset by unfavorable payer mix due to lower exchange admissions.” FY 2026 Adjusted EBITDA outlook raised to $4.83–$5.03 billion (SEC EX-99.1; Tenet IR).

On the Q2 call, CFO Sun Park: exchange revenues −17% (about 5.5% of consolidated NOR); exchange admissions −13.5%; ~$65 million Q2 exchange revenue headwind; “pretty consistent conversion from exchange patient volume into uninsured on a pretty much one-to-one basis”; “we expect the overall market trends that we saw in Q2 to roughly continue into Q3 and Q4 rest of the year, which is why we didn’t change our guidance” on that vector (THC Q2 call). Highest named state impacts: Florida, Arizona, Michigan, South Carolina, Texas (same call).

Tenet’s Q2 supplemental (MarketScreener reprint of the 24 Jul IR package) tables uncompensated care = implicit price concessions + charity write-offs + uninsured discounts: $2,361 million in Q2 2026 vs $1,880 million in Q2 2025; uncompensated-care percentage 29.6% vs 26.3% of net operating revenues excluding uncompensated care (MarketScreener supplemental). That is a reprint, not the SEC 99.1 HTML (the 99.1 dump did not carry this table).

Raised earnings outlook is not a surgical-volume snapback. Cases are still slightly negative; management is explicit that exchange erosion continues into 2H.

UHS: surgeries −0.8%; exchanges −15%; ~$20 million Q2 / ~$85 million FY; sequential improvement, not snapback

UHS 28 Jul 2026 call (results announced with a revised FY forecast): same-facility acute-care adjusted admissions +2.9%; ED visits +4%; same-facility surgeries −0.8%. “Although surgical volumes continue to be somewhat muted, the trend in the Q2 improved slightly compared to the past several quarters.” Exchange volumes −15% vs Q2 2025; estimated Q2 exchange impact ~$20 million, “in line”; FY pretax exchange impact moved to the upper half of the original range, ~$85 million (from a ~$75 million prior). “The reduction in the number of exchange volumes corresponds to the increase in self-pay volumes.” Filton in Q&A: “the decline in exchange volumes was offset almost on a direct one-for-one basis to an increase in self-pay volume. It felt like virtually everyone who lost their exchange coverage became an uninsured patient.” Original assumption that 10–20% would replace exchange coverage with other commercial did not hold (UHS Q2 call). Acute-care FY volume guide tightened to +1.5% to +2.5% adjusted admissions. Guidance cut at the Adjusted EBITDA-less-NCI midpoint is attributed mainly to PL/GL, D.C. de novo, and a Texas behavioral recertification — not to a surprise exchange miss vs the original band (same call; UHS EX-99.1).

A later Morgan Stanley conference reprint (FY 2026 label on stockanalysis) restates Q2 surgeries −0.8% as an improvement vs prior quarters, with inpatient surgeries up and lower-acuity GI/ENT migrating to ASCs/offices (UHS MS conference). That is channel/acuity mix, not a printed 2H elective snapback.

CYH: half of adj.-admission growth uninsured; IP surgeries −3.8%; charity up; 2H assumed similar, not a rebound

CYH Q2 call (23 Jul 2026): same-store net revenue +2.4%; admissions +1.9%; adjusted admissions +2.9%; “approximately half of that volume growth was driven by uninsured visits with minimal related net revenue.” Same-store surgeries −0.1%; inpatient surgeries −3.8%. Uncompensated/self-pay visits from “just shy of 5%” of visits prior year to “just over 6%” — “roughly a 20% increase.” Hammons attributes commercial elective softness to “consumer insecurity related to geopolitical instability and inflationary pressures,” while Johnson ties HIX disenrollment to higher self-pay and raises the FY Adjusted EBITDA HIX impact from $20–$30 million to $50–$75 million, with Q2 EBITDA impact ~$20 million and H1 ~$25 million. “We do think the back half of the year looks like the second quarter.” Hammons: “encouraged by the improving volume and surgical trends we witnessed exiting the quarter,” and “more cautious about the second half,” so outlook was cut (revenue $11.4–$11.6 billion; Adjusted EBITDA $1.3–$1.375 billion in the transcript range) (CYH Q2 call).

CYH 10-Q charity-care (standard charges, excluded from NOR): $519 million in the three months ended 30 Jun 2026 vs $334 million in 2025; estimated cost $50 million vs $34 million. H1 charity charges $863 million vs $642 million. The same 10-Q discloses a year-end 2025 charity-policy update that increased the number of accounts qualifying — so the charge jump is not a clean EPTC-only series (CYH 10-Q). Self-pay revenues 1.4% of NOR in Q2 2026 vs 0.6% in Q2 2025 (same 10-Q).

Cross-issuer: Q2 attributes volume/mix to ACA exchange exodus; 2H snapback is not in the fetched text

Q3 2026 is unprinted. Do not infer a snapback from Tenet’s raised EBITDA guide, UHS’s sequential surgery improvement, CYH’s “exiting the quarter” comment, or HCA’s “possible” Q4 deductible season.

Contradictions and open questions

• House-passed ≠ enacted. H.R. 1834’s text would have been a three-year extension. It is not law. A later must-pass rider after 10 Feb 2026 is not in the fetched congress.gov history; issuer speech through 9 Sep still treats EPTCs as expired. A November 2026 lame-duck or CR attachment remains an open legislative path (ASTHO flagged that possibility in January).
• Deferral vs permanent attrition is still open at the industry level, but the issuer 2H tell the mechanism page wanted has not printed a snapback. HCA says newly uninsured did not cut utilization the way the original model assumed (Marks) and elective surgery is down (Hazen). Those two statements sit together: uninsured still present in the ER/inpatient book; deferrable electives are the soft piece.
• Tenet vs HCA on “consumer pullback.” Tenet’s printed case declines are smaller; Sutaria (Becker’s secondary, not fetched as a load-bearing primary this pass) has been quoted denying a broad consumer retreat. The fetched Tenet IR/transcript still show exchange-to-uninsured mix and slightly negative cases. Do not upgrade Becker’s to a primary.
• CYH charity-policy change (2025) contaminates YoY charity charges. Use visit-mix (+~110 bp self-pay/uncompensated share) and the HIX EBITDA range alongside, not the $519 vs $334 million charge pair alone.
• HCA $1.0–$1.2 billion is now in the issuer release and 10-Q/call, not a Fierce snippet. The older “up to $1.1 billion” / “~$400 million Q2” mechanism-page figures match the primary ($400 million Q2 pretax; $1.0–$1.2 billion FY). Use the primary range.
• CMS effectuated-enrollment census later in 2026 and Q3 10-Qs (typical window late Oct) are the next primaries. KFF’s state-level February effectuated page timed out here.
• CBO 2.2 million remains a 2024 projection. Realized 2026 uninsured counts were not fetched from CBO/CMS this pass.

Provenance

Rounds run: 3 of 3 (full). No early exit — R3 was needed for congress.gov history + Tenet transcript + Sep HCA conference.

Sub-questions by round:

Round 1 (broad survey):

1. Has Congress extended (full or partial) the ACA enhanced premium tax credits after the end-2025 sunset?
2. What do HCA Q2 (or later) 2026 IR / 10-Q / transcript say about same-facility surgical volume and ACA/exchange attribution?
3. What do THC / UHS / CYH Q2 2026 IR say about elective/outpatient volume and uncompensated care?
4. Has any printed 2H 2026 hospital series shown deferred elective volume snapping back?
5. What is current uncompensated-care evidence (issuer 10-Q / CMS / KFF)?

Round 2 (drill-down):

1. UHS Q2 2026 EX-99.1 + transcript — targeting the R1 peer-IR gap.
2. CYH Q2 2026 10-Q + transcript — targeting Healthcare Dive/Fierce secondaries.
3. Post–February 2026 APTC legislative status (Senate CARE Act / later statute) — targeting the H.R. 1834 “Passed House only” gap.
4. Any Q3 preview or September conference line on 2H surgery rebound — targeting the step-3 falsifier.

Round 3 (resolve remaining uncertainty):

1. congress.gov H.R. 1834 history / latest action — targeting “became law or not.”
2. Tenet Q2 transcript + IR (exchange admissions, 2H comment) — targeting ACA-vs-snapback attribution in Sutaria/Park’s own words.
3. Confirm Q3 2026 remains unprinted as of 19 Sep 2026.

Anchor source (Grokipedia, fetched before round 1; encyclopedic primer only):

• Affordable Care Act — helper JSON, ~8,017 chars extracted (truncated), 314 citations — 2010 statute, Medicaid expansion, marketplace subsidies; not used for 2026 hospital or APTC-extension claims.
• Premium tax credit — helper JSON, ~6,017 chars extracted (truncated), 65 citations — IRC §36B structure; ARPA/IRA enhancement 2021–2025 and “projections indicating significant premium increases post-2025 expiration”; not used as the sole or load-bearing source for 2026 outcomes.

URLs fetched (14 successful with extractable body, 2 failed, 1 thin official landing):

Round 1:

• HCA Healthcare Reports Second Quarter 2026 Results — official IR — Q2 volumes, $400 million pretax mix, $1.0–$1.2 billion FY exchange assumption, guidance cut.
• HCA Form 10-Q for quarter ended June 30, 2026 — SEC primary — EPTC language, uninsured-admission rates, uncompensated-care dollars.
• HCA Q2 2026 earnings call transcript — transcript reprint — one-for-one uninsured, elective −6%, “have to see” on recovery.
• Tenet EX-99.1 Q2 2026 earnings release — SEC primary — hospital/USPI case rates, mix language, raised outlook.
• KFF, What We Know So Far About 2026 ACA Marketplace Enrollment… — KFF (Reliable) — 58% net premiums, 114% caveat, deductibles, 9% uninsured survey.
• [Failed: https://www.congress.gov/bill/119th-congress/house-bill/1834] — WebFetch timeout (overview). History/text recovered in R3 via search extract + later fetches.
• [Failed: https://www.kff.org/affordable-care-act/how-has-aca-marketplace-enrollment-changed-across-states-in-2026/] — WebFetch timeout. Not cited.
• CBO publication 59230 landing — official but thin HTML (title/summary only). 2.2 million figure corroborated via AHA 6 Dec 2024 recap — treat as the known pre-expiry projection.

Round 2:

• UHS EX-99.1 Q2 2026 — SEC primary — results, FY forecast revise, EPTC-beyond-2025 language.
• UHS Q2 2026 earnings call transcript — transcript reprint — surgeries −0.8%, exchanges −15%, $20 million / $85 million.
• CYH Q2 2026 earnings call transcript — transcript reprint — uninsured half of adj.-admission growth; IP sx −3.8%; HIX $50–75 million FY.
• CYH Form 10-Q for quarter ended June 30, 2026 — SEC primary — charity charges/cost; 2025 policy change caveat.
• HCA at Wells Fargo 21st Annual Healthcare Conference — transcript reprint (dated 9 Sep 2026) — “does not consider a rebound in surgery.”

Round 3:

• H.R. 1834 history / Congressional Record — congress.gov — last Senate calendar action 10 Feb 2026; not Became Law.
• H.R. 1834 text — congress.gov — three-year extension language (counterfactual statute).
• Tenet Q2 2026 earnings call transcript — transcript reprint — −13.5% exchange admissions; 2H continuation.
• Tenet IR Q2 2026 release — official IR — mix vs raised outlook.
• ASTHO, ACA Enhanced PTCs legislative developments — state-health-official recap (20 Jan 2026) — S. 3385 fail; CARE Act unfinished.
• AHA, House passes bill… — trade association — 230–196; credits “expired at the end of December.”
• Tenet Q2 supplemental uncompensated-care table (MarketScreener reprint) — IR-package reprint — $2.361 billion / 29.6%.

Not fetched (routed around or out of budget): Fierce Healthcare (user note / likely 403); www.reuters.com (Hard-blocked); www.cnbc.com (Persistent-failure); www.hhs.gov (Persistent-failure); CMS HTML (Periodic-failure timeout risk) — used KFF’s CMS-based analysis instead; Urban Institute off-whitelist PDF not used as a 2026 realized figure.

SOURCE_RELIABILITY notes: Preferred investor.hcahealthcare.com, www.sec.gov, www.congress.gov, www.kff.org, www.cbo.gov, www.aha.org, issuer IR. kffhealthnews.org is listed Reliable; kff.org fetched cleanly this pass. cms.gov Periodic-failure — not attempted. Fierce not used. Transcript reprints via stockanalysis.com (Reliable in tracker) used when issuer IR HTML lacked Q&A.

Tools used: WebSearch, WebFetch, python3 .claude/skills/_lib/grokipedia.py fetch (Affordable_Care_Act; Premium_tax_credit). Priors skipped per request. No X pass. No promote, ingest, wiki, or sources/ edit.

Generated: 2026-09-19 UTC